Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage oncology and obesity company whose news flow is driven by clinical trial progress, regulatory milestones, and capital markets activity. The company regularly issues press releases on Phase 1 and Phase 2 data for its investigational drug candidates, as well as updates on financing transactions and participation in major healthcare conferences.
Investors following CRBP news can expect detailed updates on CRB-701, Corbus’ Nectin-4–targeting antibody-drug conjugate being studied in a multi-center Phase 1/2 trial in advanced solid tumors such as head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial cancer. News items have highlighted objective response rates, disease control rates, safety findings, and Fast Track designations granted by the U.S. Food and Drug Administration. Corbus also announces presentations of CRB-701 data at scientific meetings like the European Society for Medical Oncology Congress and associated key opinion leader events.
Another major news theme is the company’s obesity program, particularly CRB-913, a highly peripherally restricted oral CB1 receptor inverse agonist. Corbus has reported results from a Phase 1a SAD/MAD study in the United States, including safety, tolerability, pharmacokinetic data, and emerging evidence of weight loss in people with obesity. Subsequent news covers the initiation and design of the 12‑week CANYON‑1 Phase 1b study in obese, non-diabetic participants.
Corbus’ news feed also includes quarterly financial results, preliminary financial updates via Form 8‑K, and announcements of underwritten public offerings of common stock and pre-funded warrants. In addition, the company frequently discloses its participation in investor conferences and healthcare symposia, where it presents corporate overviews and engages in one-on-one investor meetings. Bookmarking the CRBP news page on Stock Titan allows readers to track these clinical, regulatory, and financing developments in one place.
Corbus Pharmaceuticals (NASDAQ: CRBP) has initiated the Phase 1 clinical trial of CRB-601, dosing its first patient for the treatment of advanced solid tumors. CRB-601 is a monoclonal antibody targeting latent TGFβ activation by blocking the integrin αVβ8.
Pre-clinical data has shown that CRB-601 successfully overcomes tumor immune exclusion and enhances the effectiveness of immune checkpoint inhibitors in vivo. The study (NCT06603844) represents a significant step in evaluating CRB-601's potential in immunotherapy and its ability to modulate TGFβ signaling.
Corbus Pharmaceuticals announced that the FDA has granted Fast Track designation to CRB-701 for treating relapsed or refractory metastatic cervical cancer. CRB-701 is a next-generation antibody drug conjugate targeting Nectin-4, featuring a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE payload. The company has completed enrollment for the dose escalation portion of its Phase 1 clinical trial, which is evaluating safety, pharmacokinetics, and efficacy in patients with advanced solid tumors associated with high Nectin-4 expression. Initial data from the dose escalation study is expected in Q1 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the 7th Annual Evercore HealthCONx Conference, scheduled for December 3-5, 2024, in Coral Gables, FL. CEO Yuval Cohen, Ph.D., will engage in a fireside chat and conduct one-on-one investor meetings during the event. The fireside chat is specifically scheduled for December 3, 2024, at 4:15 p.m. ET, with a webcast available for viewing.
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the upcoming Jefferies London Healthcare Conference, scheduled for November 19-21, 2024, in London, UK. The company's CEO, Yuval Cohen, Ph.D., will engage in a fireside chat and conduct one-on-one investor meetings during the event. The fireside chat is specifically scheduled for November 19, 2024, at 10:30 a.m. GMT, with a webcast link provided for interested parties.
Corbus Pharmaceuticals reported Q3 2024 financial results and corporate updates. The company completed enrollment for the dose escalation part of its Phase 1 trial for CRB-701, with first data expected in Q1 2025. New pre-clinical data for CRB-913 was presented at Obesity Week 2024, with Phase 1 trial expected to start in Q1 2025. The company reported a net loss of $13.8 million, or $1.15 per share. Operating expenses increased to $15.5 million. Cash position stands at $159.4 million, expected to fund operations through Q3 2027. The company raised $35.6 million through ATM program and paid off an $11.8 million loan.
Corbus Pharmaceuticals (NASDAQ: CRBP) presented new pre-clinical data for CRB-913, its CB1 inverse agonist, at Obesity Week 2024. Key findings show CRB-913's brain levels are 15-fold lower than monlunabant, with a 10 times higher plasma-to-brain ratio. The compound demonstrated significant weight loss of up to 38% in DIO mice at doses ranging from 5 to 80 mg/kg/day. Notably, when replacing semaglutide treatment, CRB-913 maintained weight loss and doubled fat reduction compared to semaglutide maintenance. The company plans to begin Phase 1 clinical trials in Q1 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the upcoming Guggenheim Securities Healthcare Innovation Conference in Boston, MA. The company's CEO, Yuval Cohen, Ph.D., will engage in a fireside chat and conduct one-on-one investor meetings during the event, which runs from November 11-13, 2024. Dr. Cohen's fireside chat is scheduled for November 12, 2024, at 10:00 a.m. ET, and will be available via webcast.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the BMO Capital Markets' Oncology Summit on October 8, 2024, in New York, NY. The company's Chief Medical Officer, Dr. Dominic Smethurst, will be part of a panel discussion titled 'Capitalizing on Validated Mechanism in Oncology' at 1:30 pm ET.
Additionally, Dr. Smethurst and Yuval Cohen, Ph.D., the Chief Executive Officer of Corbus, will be available for one-on-one investor meetings during the event. Interested parties are advised to contact their BMO Capital Markets sales representative for registration details.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the 2024 Cantor Global Health Conference, scheduled for September 17-19, 2024, in New York City. The company's CEO, Yuval Cohen, Ph.D., will be presenting at the event.
Key details of the presentation include:
- Date: September 17, 2024
- Time: 8:00 AM Eastern Time
- Location: InterContinental New York Barclay Hotel
- Format: Fireside chat with Cantor analyst Prakhar Agrawal
Dr. Cohen will also be available for one-on-one investor meetings during the conference. A webcast link for the presentation has been provided for those unable to attend in person.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has appointed Winston Kung to its Board of Directors, effective August 16, 2024. Mr. Kung, who will also chair the Audit Committee, brings over 20 years of leadership experience in life sciences and investment banking. Currently serving as CFO of Arrivent BioPharma, he has held senior positions at PMV Pharmaceuticals, Celgene, Citigroup, Lehman Brothers, Genentech, and Amgen.
The company's leadership expressed enthusiasm for Mr. Kung's expertise in pharma industry and capital markets, viewing his appointment as valuable for advancing Corbus' pipeline. Simultaneously, Avery "Chip" Catlin has resigned from the Board and as Audit Committee Chair after serving for over ten years.